Mylan Loses Court Fight Over Multiple Sclerosis Drug

by Vishnuprasad on  January 22, 2015 at 7:11 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

The Supreme Court has ruled against generic drugmaker Mylan Inc. and other firms in their challenge of Teva Pharmaceutical Industries' patents for a blockbuster multiple sclerosis drug.
Mylan Loses Court Fight Over Multiple Sclerosis Drug
Mylan Loses Court Fight Over Multiple Sclerosis Drug

The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone, which generates about $4 billion in annual sales for Teva. The majority told a lower court to reconsider a ruling invalidating the patents.

The decision allows the Israel-based company to keep its exclusive rights to Copaxone until September, delaying generic competition from Mylan and the other companies. And it gives Teva more time to shift patients to a longer acting version that won't face competition until 2030.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Chemotherapy Chemotherapy Drugs Signature Drug Toxicity Infectious Mononucleosis Multiple Sclerosis Treatment and Modify Optic Neuritis Autoimmune Disorders Health Risks of Eating Pork 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...